Fouremm -  agreed 

" (you have to look hard to find another quality science ph3 program with a market cap of less than $25M). "

The huge disparity between market potential(89B conservative estimate) and market cap(25M and falling) indicates to me that something is amiss. RVX's late stage Phase3 BTD therapy has no value? 

Is it a quality science program? Something is seriously wrong here. 

Chicagoest